Systematic review on the use of cannabidiol (CBD) as an alternative therapy in patients with cancer diagnoses
Article Sidebar
Publicación 7. Vol 6. Num 3 (Español (España))
HTML (Español (España))
EPUB (Español (España))
FLIP (Español (España))
Published:
Jul 20, 2023
Keywords:
Marijuana, cannabis, cannabidiol, cancer, symptomatologic treatment.
Main Article Content
Abstract
Introduction. Cannabidiol (CBD) is a compound derived from the Cannabis sativa plant, which has garnered significant interest due to its pharmacological properties. CBD is being increasingly used in the treatment of various conditions, particularly cancer. As a result, numerous clinical trials have demonstrated its potential in managing chemotherapy side effects, thereby improving patients' quality of life and treatment adherence. Objective. This systematic review aims to analyze the most recent scientific evidence to describe the use of CBD as an alternative therapy in patients diagnosed with cancer. Methodology. The review follows the PRISMA guidelines, employing a quantitative exploratory research design with a bibliographic approach that adheres to the standards of quality and transparency expected by the scientific community and other interested parties. Results. CBD, when used as an adjunct to the therapeutic regimen, has shown promise in counteracting the side effects of chemotherapy. However, limited research and control over this drug have revealed cognitive effects in several patients. Conclusion. This review compiles recent data on the use of CBD, suggesting beneficial effects in reducing cancer-related symptoms and the side effects of conventional treatments. It generates a discussion on the efficacy of CBD as part of an oncological therapeutic regimen.
Downloads
Download data is not yet available.
Article Details
How to Cite
González Carrión, B. N., Guzmán Coronel, J. S., & Araujo Campoverde, M. V. (2023). Systematic review on the use of cannabidiol (CBD) as an alternative therapy in patients with cancer diagnoses. ConcienciaDigital, 6(3), 102-116. https://doi.org/10.33262/concienciadigital.v6i3.2625
Section
Artículos
References
American Cancer Society. (2023, junio 8). Datos sobre el dolor causado por el cáncer. https://www.cancer.org/es/cancer/como-sobrellevar-el-cancer/efectos-secundarios/dolor/datos-sobre-el-dolor-causado-por-el-cancer.html
Bravo, M., Letty, E., & Adriana, M. (2023). El cannabis como agente terapéutico en Ecuador, repercusión económica contable. Revista Cubana de Reumatología, 25(2). https://revreumatologia.sld.cu/index.php/reumatologia/article/view/1127
Brisbois, T., de Kock, I., Watanabe, S., MacDonald, N., Baracos, V., & Wismer, W. (2011). Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Original Articles Quality of Life and Supportive Care, 22(9), 2086-2093. https://doi.org/10.1093/annonc/mdq727
Chang, Y., Zhu, M., Vannabouathong, C., Mundi, R., Chou, R., & Bhandari, M. (2021). Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations. Pain Research and Management, 2021, 1203-6765. doi:10.1155/2021/8857948
Fallon, M., Lux, A., McQuade, R., Rossetti, S., Sanchez, R., Sun, W., &. Kornyeyeva, E. (2017, Agosto 11). Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain, 11(3), 119-133. doi:10.1177/2049463717710042.
Good, P., Greer, R., Huggett, G., & Hardy, J. (2020, may). An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care. J Palliat Med, 23(5), 650-655. doi:10.1089/jpm.2019.0540
Guijarra, L. (2021, abril 06). El Cannabis: Un Mercado De Expansión En El Ecuador. Obtenido de https://laboratoriolasa.com/el-cannabis-un-mercado-de-expansion-en-el-ecuador/#:~:text=El%20Ecuador%20ha%20decidido%20incursionar,como%20tambi%C3%A9n%20de%20c%C3%A1%C3%B1amo%20industrial.
Häuser, W., Welsch, P., Klose, P., Radbruch, L., & Fitzcharles, M.-A. (2019, octubre). Efficacy, tolerability, and safety of cannabis-based medicines for cancer pain: A systematic review with meta-analysis of randomized controlled trials. Schmerz, 424-436. doi:10.1007/s00482-019-0373-3
Lev Schleider, L. B., Mechoulam, R., Lederman, V., Betzalel, O., Shbiro, L., & Novack, V. (2018). Prospective analysis of safety and efficacy of medical cannabis in large, unselected population of patients with cancer. Journal of International Medicine, 49, 37-43. https://doi.org/10.1016/j.ejim.2018.01.023
Licthman, A., Lux, E., McQuade, R., Wrigth, S., Kornyeyeva, E., & Fallon, M. (2017. September 15). Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. JPSM, 55(2), 169-178. https://doi.org/10.1016/j.jpainsymman.2017.09.001
Mohiuddin, M., Di Forti, M., Eccleston, C., Blyth, F., Degenhardt, L., Simon, H., & Ian, G. (2021). General risks of harm with cannabinoids, cannabis, and cannabis-based medicine relevant to patients receiving these for pain management: an overview of systematic reviews. Pain, 80-96. doi:10.1097/j.pain.0000000000002000
Mücke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H., & Conrad, R. (2018, April). Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle, 9(2), 220-234. doi:10.1002/jcsm.12273
Ng, J. Y., Abrams, A., Pathak, A., Tahir, U., & Jomy, J. (2022). What are the experiences of patients using cannabis for pain? A systematic review of qualitative studies. European Journal of Integrative Medicine, 49, 1876-3820. https://doi.org/10.1016/j.eujim.2021.102098
Organización Mundial de la Salud [OMS]. (8 de junio de 2023). Report about cacer. https://www.who.int/es/news-room/fact-sheets/detail/cancer
Portenoy, R. K., Ganae-Motan, E. D., Allende, S., McQuade, R., Wright, S., & Fallon, M. T. (09 de May de 2018). Nabiximols for Opioid-Treated Cancer Patients with Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial. The Journal of Pain, 13(5), 438-449. https://doi.org/10.1016/j.jpain.2012.01.003
Sánchez, C. (2018). Fundación CANNA. https://www.fundacion-canna.es/vias-de-administracion-y-productos-cannabicos-con-fines-terapeuticos
Tateo, S. (2017). State of the evidence: Cannabinoids and cancer pain-A systematic review. J Am Assoc Nurse Pract, 29(2), 94-103. doi:10.1002/2327-6924.12422
Turcott, J. G., Núñez, M., Estrada, D., Oñate, L., Zatarain, Z., Barron, F., & Arrieta, O. (2018). The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Randomized Controlled Trial, 26(9), 3029-3038. doi:10.1007/s00520-018-4154-9
Bravo, M., Letty, E., & Adriana, M. (2023). El cannabis como agente terapéutico en Ecuador, repercusión económica contable. Revista Cubana de Reumatología, 25(2). https://revreumatologia.sld.cu/index.php/reumatologia/article/view/1127
Brisbois, T., de Kock, I., Watanabe, S., MacDonald, N., Baracos, V., & Wismer, W. (2011). Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Original Articles Quality of Life and Supportive Care, 22(9), 2086-2093. https://doi.org/10.1093/annonc/mdq727
Chang, Y., Zhu, M., Vannabouathong, C., Mundi, R., Chou, R., & Bhandari, M. (2021). Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations. Pain Research and Management, 2021, 1203-6765. doi:10.1155/2021/8857948
Fallon, M., Lux, A., McQuade, R., Rossetti, S., Sanchez, R., Sun, W., &. Kornyeyeva, E. (2017, Agosto 11). Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain, 11(3), 119-133. doi:10.1177/2049463717710042.
Good, P., Greer, R., Huggett, G., & Hardy, J. (2020, may). An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care. J Palliat Med, 23(5), 650-655. doi:10.1089/jpm.2019.0540
Guijarra, L. (2021, abril 06). El Cannabis: Un Mercado De Expansión En El Ecuador. Obtenido de https://laboratoriolasa.com/el-cannabis-un-mercado-de-expansion-en-el-ecuador/#:~:text=El%20Ecuador%20ha%20decidido%20incursionar,como%20tambi%C3%A9n%20de%20c%C3%A1%C3%B1amo%20industrial.
Häuser, W., Welsch, P., Klose, P., Radbruch, L., & Fitzcharles, M.-A. (2019, octubre). Efficacy, tolerability, and safety of cannabis-based medicines for cancer pain: A systematic review with meta-analysis of randomized controlled trials. Schmerz, 424-436. doi:10.1007/s00482-019-0373-3
Lev Schleider, L. B., Mechoulam, R., Lederman, V., Betzalel, O., Shbiro, L., & Novack, V. (2018). Prospective analysis of safety and efficacy of medical cannabis in large, unselected population of patients with cancer. Journal of International Medicine, 49, 37-43. https://doi.org/10.1016/j.ejim.2018.01.023
Licthman, A., Lux, E., McQuade, R., Wrigth, S., Kornyeyeva, E., & Fallon, M. (2017. September 15). Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. JPSM, 55(2), 169-178. https://doi.org/10.1016/j.jpainsymman.2017.09.001
Mohiuddin, M., Di Forti, M., Eccleston, C., Blyth, F., Degenhardt, L., Simon, H., & Ian, G. (2021). General risks of harm with cannabinoids, cannabis, and cannabis-based medicine relevant to patients receiving these for pain management: an overview of systematic reviews. Pain, 80-96. doi:10.1097/j.pain.0000000000002000
Mücke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H., & Conrad, R. (2018, April). Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle, 9(2), 220-234. doi:10.1002/jcsm.12273
Ng, J. Y., Abrams, A., Pathak, A., Tahir, U., & Jomy, J. (2022). What are the experiences of patients using cannabis for pain? A systematic review of qualitative studies. European Journal of Integrative Medicine, 49, 1876-3820. https://doi.org/10.1016/j.eujim.2021.102098
Organización Mundial de la Salud [OMS]. (8 de junio de 2023). Report about cacer. https://www.who.int/es/news-room/fact-sheets/detail/cancer
Portenoy, R. K., Ganae-Motan, E. D., Allende, S., McQuade, R., Wright, S., & Fallon, M. T. (09 de May de 2018). Nabiximols for Opioid-Treated Cancer Patients with Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial. The Journal of Pain, 13(5), 438-449. https://doi.org/10.1016/j.jpain.2012.01.003
Sánchez, C. (2018). Fundación CANNA. https://www.fundacion-canna.es/vias-de-administracion-y-productos-cannabicos-con-fines-terapeuticos
Tateo, S. (2017). State of the evidence: Cannabinoids and cancer pain-A systematic review. J Am Assoc Nurse Pract, 29(2), 94-103. doi:10.1002/2327-6924.12422
Turcott, J. G., Núñez, M., Estrada, D., Oñate, L., Zatarain, Z., Barron, F., & Arrieta, O. (2018). The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Randomized Controlled Trial, 26(9), 3029-3038. doi:10.1007/s00520-018-4154-9